Hemant Bid Selected Research

SAR405838

1/2022	Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
3/2016	SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hemant Bid Research Topics

Disease

4	Neoplasms (Cancer) 01/2021 - 08/2010
2	Liposarcoma 01/2022 - 03/2016
1	Genomic Instability 03/2016
1	Sarcoma (Soft Tissue Sarcoma) 03/2016
1	Hepatocellular Carcinoma (Hepatoma) 12/2013
1	Cysts 12/2013
1	Neoplasm Metastasis (Metastasis) 12/2013

Drug/Important Bio-Agent (IBA)

2	SAR405838IBA 01/2022 - 03/2016
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021
1	tetraethylpyrazine (TEP)IBA 01/2021
1	MicroRNAs (MicroRNA)IBA 01/2021
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 12/2013
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2013
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2013
1	adipic dihydrazideIBA 08/2010
1	AminesIBA 08/2010
1	polyethylene glycol-poly(lactide-co-glycolide)IBA 08/2010
1	Fluorouracil (Carac)FDA LinkGeneric 08/2010

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 08/2010